Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio?

Amylyx at a Crossroads: Can the Company Overcome the Loss of Relyvrio?

Source: 
BioSpace
News Tags: 
snippet: 

A biopharma company that began as an idea in a dorm room at Brown University has suffered a critical setback—but some experts believe Amylyx may be able to overcome the loss of its only marketed product.

On April 4, the Cambridge, Mass.–based company announced it would pull Relyvrio/Albrioza from U.S. and Canadian markets and part with around 70% of its employees after the amyotrophic lateral sclerosis (ALS) drug failed a Phase III clinical trial. In doing so, Amylyx co-CEOs Justin Klee and Josh Cohen made good on a pledge to a 2022 FDA advisory committee to withdraw the drug if the Phase III PHOENIX trial was not successful.